BioVie Preps KOL Event Ahead of Parkinson’s Drug Data Drop
Event summary
- BioVie to host virtual KOL event on May 7, 2026, featuring Suzanne de la Monte to discuss bezisterim’s mechanism of action in Parkinson’s disease.
- Phase 2 trial results for bezisterim (NE3107) in Parkinson’s expected mid-2026.
- Bezisterim also being studied for Long COVID and Alzheimer’s with topline data due mid-2026.
The big picture
BioVie is positioning itself as a key player in neuroinflammation and insulin resistance therapies, targeting high-prevalence diseases like Parkinson’s, Alzheimer’s, and Long COVID. The upcoming KOL event underscores the strategic importance of bezisterim’s mechanism of action, which could differentiate it in a crowded neurodegenerative disease space.
What we're watching
- Data Readout Impact
- How bezisterim’s Phase 2 results will position BioVie in the competitive Parkinson’s disease market.
- Pipeline Diversification
- Whether BioVie can sustain momentum across multiple indications, including Long COVID and Alzheimer’s.
- Regulatory Pathway
- The pace at which bezisterim advances through clinical trials given its broad therapeutic potential.
Related topics